Fate Therapeutics Inc (FATE) Company Profile & Statistics

Fate Therapeutics Inc
FATE
(Nasdaq - US)
Open
4.20
-0.34 (-7.49%)
in:usd•As of: Apr 24, 2024 13:22 UTC -4
Open
4.61
High
4.61
Low
4.18

About Fate Therapeutics Inc

CEO

J. Scott Wolchko

Headquarters

12278 scripps summit drive

san diego, ca 92131, united states

Auditor

Ernst & Young, LLP

Employees

181

Share Holders

Website

www.fatetherapeutics.com

Industry

biotechnology

Sector

health technology

Company Overview

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.

Fate Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	478.04M
Enterprise Value	436.17M
Enterprise Value/EBITDA (ttm)	-2.47
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.28
Price to Sales (ttm)	8.56
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-253.30%
Profit Margin (ttm)	-2660.62%
Return on Equity (ttm)	-38.17%
Return on Invested Capital (ttm)	-39.20%
Return on Assets (ttm)	-28.42%

Income Statement

Revenue (ttm)	63.53M
Revenue Per Share (ttm)	0.64
Gross Profit (ttm)	63.53M
EBITDA (ttm)³	-176.43M
Net Income Avi to Common (ttm)	-160.93M
Diluted EPS (ttm)	-1.64

Share Statistics

Beta (5Y Monthly)	1.66
52-Week Change	-33.75%
S&P500 52-Week Change	22.29%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	99.24M
Dividend Yield	0.00%
Float ⁴	108.08M
% Held by Insiders	5.04%
% Held by Institutions	97.54%

Balance Sheet

Total Cash (mrq)	315.18M
Total Cash Per Share (mrq)	3.18
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	8.48%
Quick Ratio (mrq)	8.48%
Book Value Per Share (mrq)	3.74

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.34
Free Cash Flow (ytd)	-138.42M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Fate Therapeutics Inc

Trade With A Regulated Broker